Thursday, July 29, 2021

TOPICS

Home Tags Dr. Pablo J. Cagnoni

Tag: Dr. Pablo J. Cagnoni

Rubius Therapeutics posts $42.3M loss in Q1

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
RUBIUS THERAPEUTICS ended 2020 with a loss of $167.7 million.

Rubius Therapeutics reports $167.7M loss in 2020

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share. The clinical-stage biopharmaceutical company, which...

Rubius announces 3 new patents for cellular-therapy program

PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases,...

Rubius appoints Holles to board, Whitehead as SVP, chief quality officer

PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality...

Stay up to date with PBN's Morning Call & Daily Edition newsletters.

- Featured Event -

Latest News

Register to read all articles free - This week only!

CLOSE

One week only, get full access to all articles on PBN.com when you create a complimentary account.

One week only, get full access to all articles on PBN.com when you create a complimentary account.

 

Register today >>

Sign-up to get the

PBN Daily Edition

A collection of all the published news of the last 24 hours, as well as selected features from PBN’s weekly print edition.

By submitting the form you agree to PBN's Privacy Policy and Terms of Use.

We’re glad you are enjoying PBN.